» Articles » PMID: 9258764

Standardization of Femur BMD

Overview
Date 1997 Aug 1
PMID 9258764
Citations 48
Authors
Affiliations
Soon will be listed here.
Citing Articles

Long-term changes in bone mineral density and associated risk factors in individuals with spinal cord injury: A retrospective study.

Mun C, Sho K, Kim O Medicine (Baltimore). 2024; 103(39):e39790.

PMID: 39331903 PMC: 11441903. DOI: 10.1097/MD.0000000000039790.


Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project.

Schini M, Vilaca T, Lui L, Ewing S, Thompson A, Vittinghoff E J Bone Miner Res. 2024; 39(7):867-876.

PMID: 38691441 PMC: 11301522. DOI: 10.1093/jbmr/zjae068.


Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study.

Brown J, Paggiosi M, Rathbone E, Gregory W, Bertelli G, Din O J Bone Miner Res. 2024; 39(1):8-16.

PMID: 38630878 PMC: 11207765. DOI: 10.1093/jbmr/zjad006.


Characteristics Associated with Bone Loss after Spinal Cord Injury: Implications for Hip Region Vulnerability.

Han S, Shin S, Kim O, Hong N Endocrinol Metab (Seoul). 2023; 38(5):578-587.

PMID: 37816499 PMC: 10613772. DOI: 10.3803/EnM.2023.1795.


Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.

Hong N, Shin S, Lee S, Rhee Y Osteoporos Int. 2023; 34(12):2059-2067.

PMID: 37596432 DOI: 10.1007/s00198-023-06889-2.